Alexandra Tompkins, Zane N Gray, Rebekah E Dadey, Serafettin Zenkin, Nasim Batavani, Sarah Newman, Afsaneh Amouzegar, Murat Ak, Nursima Ak, Taha Yasin Pak, Vishal Peddagangireddy, Priyadarshini Mamindla, Sarah Behr, Amy Goodman, Darcy L Ploucha, John M Kirkwood, Hassane M Zarour, Yana G Najjar, Diwakar Davar, Rivka Colen, Jason J Luke, Riyue Bao
BACKGROUND: Variability in treatment response may be attributable to organ-level heterogeneity in tumor lesions. Radiomic analysis of medical images can elucidate non-invasive biomarkers of clinical outcome. Organ-specific radiomic comparison across immunotherapies and targeted therapies has not been previously reported. METHODS: We queried UPMC Hillman Cancer Center registry for patients with metastatic melanoma (MEL) treated with immune checkpoint inhibitors (ICI) (anti-PD1/CTLA4 [ipilimumab+nivolumab; I+N] or anti-PD1 monotherapy) or BRAF targeted therapy...
April 27, 2024: medRxiv